| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.17 | 0.003 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.004 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.004 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |